Revvity, Inc.

NYSE:RVTY

Medical - Diagnostics & Research

Healthcare
$152.43 -3.36%

-$3.40 today

Market cap
$17.02B
Beta
1.11
P/E (TTM)
45.4
EPS (TTM)
$2.15
Dividend yield
0.29%
52W Low $81.22High $118.30

Volume 1.09M

Average 1.27M

RVTY Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Revvity, Inc.NYSE: RVTY

Change in Working Capital · Q2 FY2026 · quarter ended Jul 2026

Change in working capital dips below year-ago levels

Q2 FY2026 change in working capital of $18.08M (cash outflow) fell 63.0% year over year, behind the +42.9% change in trailing-twelve-month change in working capital. Sequentially, it fell 53.4% from the prior quarter. Over 3 fiscal years it compounded at -28.3% a year.

Context

  • Change in working capital amounted to 3.4% of revenue in FY2025, up 2.7 pp from a year earlier.
  • Change in working capital grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -63.0% toward the trailing-twelve-month pace of +42.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJul 2026
-$18.08M-53.4% QoQ
Last fiscal yearDec 2025
-$96.78M+428.7% YoY
LTMJul 2026
-$71.52M+42.9% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.0%——
1 year+428.7%——
3-year CAGR-28.3%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(96.78M) USD
Year-over-year change
-428.7%

Change in Working Capital vs competitors

How RVTY compares with its peers on the latest reported figures

  • RVTY's LTM Jul 2026 change in working capital of $71.52M is the 7th largest of the 11 companies compared; the peer median is $57.97M.
  • Its year-over-year change of +42.9% is the 5th highest of 11, against a peer median of -45.9%.
  • Change in working capital amounts to 2.5% of revenue for RVTY, versus a peer median of 1.6%.
RVTY Competitors Peer median
Change in Working Capital for RVTY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$446M -24.9%+19.0%0.9%
AAgilent Technologies, Inc.LTM Jul 2026$288M +98.6%-50.5%3.9%
WATWaters CorporationLTM Jul 2026$252.26M +59.2%-4.6%5.4%
DHRDanaher CorporationLTM Sep 2026$229M -66.9%-22.4%0.9%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$101.45M -344.2%—2.5%
MTDMettler-Toledo International Inc.LTM Jun 2026$96.96M +465.3%-27.7%2.3%
RVTYRevvity, Inc.LTM Jul 2026$71.52M +42.9%-28.3%2.5%
TECHBio-Techne CorporationLTM Sep 2026$67.36M +412.2%-23.0%5.5%
QGENQiagen N.V.LTM Jun 2026$18.98M -164.6%+2.7%0.9%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$14.2M -105.1%—0.5%
MLABMesa Laboratories, Inc.LTM Mar 2026$516K -96.1%-33.7%0.2%
Peer median (excluding RVTY) $57.97M-45.9%-22.7%1.6%

Competitors are the stored peer set for RVTY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income889.44M512.68M179.5M283.07M241.2M
Depreciation & Amortization311.44M427M431.77M427.85M405.34M
Deferred Income Tax(53.4M)(107.41M)(97.48M)(110.31M)(61.48M)
Stock-Based Compensation29.68M51.52M41.41M37.81M22.85M
Change in Working Capital132.99M(262.97M)(391.35M)(18.31M)(96.78M)
Accounts Receivables165.59M66.09M(9M)(15.97M)(101.02M)
Inventory32.28M(48.63M)(14.11M)45.09M14.78M
Accounts Payables(7.58M)(43.8M)(76.43M)(26.03M)7.35M
Other Working Capital(57.3M)(236.62M)(291.81M)(21.4M)(17.89M)
Other Non-Cash Items100.61M59M(72.58M)8.18M70.65M
Operating Cash Flow1.41B679.81M91.27M628.3M581.78M
Capital Expenditures(86.02M)(85.63M)(81.37M)(86.65M)(73.52M)
Acquisitions (Net)(3.98B)6.99M(1.93M)00
Purchases of Investments(23.13M)(47.18M)(1.23B)(6.59M)(385K)
Sales of Investments08.89M550M712.5M0
Other Investing Activities(22.96M)(15.92M)2.07B156.9M56.55M
Investing Cash Flow(4.11B)(132.85M)1.31B776.16M(17.35M)
Debt Repayment3.04B(559.17M)(517.49M)(723.07M)(521K)
Common Stock Issued25.12M14.11M002.93M
Common Stock Repurchased(73.07M)(80.64M)(388.88M)(369.58M)(820.82M)
Dividends Paid(32.37M)(35.34M)(34.97M)(34.45M)(32.8M)
Other Financing Activities(21M)(767K)(5.79M)(1.13M)(3.84M)
Financing Cash Flow2.94B(661.8M)(947.12M)(1.13B)(855.05M)
Effect of Forex Changes(22.93M)(33.75M)(14.05M)(26.15M)46.04M
Net Change in Cash216.72M(148.59M)443.63M250.08M(244.59M)
Free Cash Flow1.32B594.18M9.9M541.65M508.26M

Revvity, Inc.

NYSE:RVTY

Intrinsic Alpha fair value

Locked

Current Price

$152.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.